<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The use of adjuvant chemotherapy has improved survival in early-stage <z:hpo ids='HP_0003003'>colon cancer</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Ongoing adjuvant clinical trials are evaluating the addition of targeted therapies to standard chemotherapy regimen </plain></SENT>
<SENT sid="2" pm="."><plain>Preliminary results with bevacizumab were disappointing </plain></SENT>
<SENT sid="3" pm="."><plain>Also, cetuximab added to chemotherapy does not seem to be better than chemotherapy alone, even in selected <z:mp ids='MP_0002169'>wild-type</z:mp> KRAS populations </plain></SENT>
<SENT sid="4" pm="."><plain>A better understanding of mechanisms of action of drugs, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> biology, and predictive biomarkers are needed to design future adjuvant trials </plain></SENT>
</text></document>